share_log

Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90

Benzinga ·  Jul 26 11:51  · Ratings

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target from $101 to $90.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment